Nicky Lawrence

Medical oncologist, interested in genitourinary malignancies and clinical trial design

[Nicky Lawrence @nickymitchell]

Very inspiring AoNZ concept development workshop today! Bring on #ACORD26 @MartinStockler

[Tom Powles @tompowles1]

1/2 Disitimab Vedotin & toripalimab beating platinum chemotherapy in 1st line UC in HER2 +ves. HRs for PFS/OS =0.36/0.56 respectively. RR and CR rate of 76% & 5% respectively. Tox related discontinuation in 12 vs 10% respectively. Working across all subsets #ESMO25 @OncoAlert

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Outstanding discussion by @AzadOncology on #PSMAaddition at #ESMO25 👉highlighting the need for a personalized approach in mHSPC #ProstateCancer 👉
pt selection, toxicity vigilance, & that not all pts need Lu-177 or 6 cycles 👉precision, not over-treatment. @OncoAlert @UroToday

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Outstanding discussion of the ENZARAD results by @Prof_Nick_James on why there is a difference in outcomes in the ENZARAD vs Stampede trial #ESMO25 @OncoAlert @urotoday @PCF_Science

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science

[Rana McKay, MD, FASCO @DrRanaMcKay]

Incredible data from EMBARK demonstrating OS benefit of ENZA + ADT for high risk BCR. ⁦@myESMO⁩ #ESMO25 ⁦@OncoAlert⁩

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Carefully done #RAMPART adjuvant trial for durvalumab in #kidneycancer, showing disease free survival benefit.
#ESMO25 @myESMO #ESMOAmbassadors @OncoAlert

[Shankar Siva @_ShankarSiva]

📣 #ESMO2025: n=565 🇬🇧🇪🇸🇦🇺🇫🇷 RAMPART RCT; Durvalumab + tremelimumab 📈boosts DFS in resected RCC #kidneycancer (HR 0.65, 2-yr 84% vs 78%), esp. in leibovich high-risk pts (HR 0.52, 81% vs 67%). G3+ AES 8% monitoring versus 40% with durva+treme. OS data eagerly awaited! #kcsm

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Clean trial of lenvatinib-everolimus vs cabozantinib in refractory #kidneycancer from @OncHahn @MDAndersonNews
#ESMO25 #ESMOAmbassadors @OncoAlert

[Daniel Heng @DrDanielHeng]

This is so cool. Imagine a world of 65% pT0 CR rates for muscle invasive bladder cancer. This is for cis ineligible but will there be scope creep? Looking forward to EV304 cis eligible. #esmo25 @OncoAlert #amazing

[Tom Powles @tompowles1]

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

[UroToday.com @urotoday]

Phase 1 trial of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced #ProstateCancer. Presentation by Jose Avitia, MD. #ESMO25 written coverage by @RKSayyid > https://t.co/NitQrmpqQA @UAUrology @myESMO @neerajaiims

[Emre Yekedüz @yekeduz_emre]

LBA110 – GDFather-NEO Trial #ESMO25
🚀 Nivolumab + visugromab (anti–GDF-15) vs NIVO + placebo as neoadjuvant Tx in MIBC.
✅ pCR: 33.3% vs 7.7%
✅ MPR: 66.7% vs 23.1%
💥 ORR: 60% vs 15%
🧬 GDF-15 blockade tripled response to PD-1 therapy with excellent tolerability.

@myESMO @DrYukselUrun @OncoAlert #Cancer #Oncology @AndreaNecchi @DrChoueiri

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science

[Michael Hofman @DrMHofman]

The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active.
✅ No dose-limiting toxicities
💪 PSA-50% decline in 55%
🧬 Supports future α+β theranostic combos.
🔗 https://t.co/AGxr0QbfCd

Congrats @LouiseKostos: what an amazing PhD!
Thank-you to @PCF_Science @pros_tic @Bayer for funding & support, co-senior author @AzadOncology, all the co-authors, wider village of contributors and most importantly our patients and their families for participating.

[Sara Coca Membribes @scocmem]

A historic moment at #ESMO25. Dr Christof Vulsteke presents
#KEYNOTE905: Periop EV + Pembro in cisplatin-ineligible MIBC:
✅ EFS HR 0.40
✅OS HR 0.50
✅pCR 57% vs 9%
Four rounds of applause from a packed room 👏

@OncoAlert @myESMO @Uromigos @urotoday

[Tom Powles @tompowles1]

Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again @OncoAlert

[Ian Davis (Bluesky @profiand) @Prof_IanD]

First @ANZUPtrials Ideas Generation Workshop in New Zealand - putting the NZ into ANZUP! Thanks to @nickymitchell and @DrCraigGedye for the warm welcome.

[Ian Davis (Bluesky @profiand) @Prof_IanD]

#ENZAMET @ANZUPtrials @TrialsCentre #ASCO25
✅ 50% survival at 8yr vs 40% - sustained, all subgroups
✅ non-#ProstateCancer deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death
✅ undetectable PSA is good; more likely with enza